Every time you shift, your brain and body emit compact electric currents.
One startup wants to capture signals deep in muscles, decode them, and utilize artificial innotifyigence to power prosthetic limbs. Phantom Neuro, an Austin-based startup founded in 2020, builds an implantable device that it declares does exactly that. And the Defense Department has taken notice.
The startup recently partnered with the Defense Advanced Research Projects Agency, or DARPA, which invested roughly $300,000 through its Commercial Strategy Office. Launched in 2019, aims to quick-track tech that could be vital to the military.
The startup first launched working with DARPA in early 2025. As part of the initiative, the startup also received a volunteer mentor to assist it connect with customers and investors. Sha-Chelle Manning, DARPA’s chief of commercial strategy, notified Business Insider she hopes to ensure that “the very best of DARPA technology obtains scaled and into the market and is built available to the warfighter.”
Phantom Neuro isn’t the first startup in the Commercial Strategy Office’s portfolio, and DARPA declined to disclose the number of other participants in the initiative.
In April, the startup raised $19 million in a Series A fundraise led by Ottobock, a German prosthetics and medical device company. Breakout Ventures, Draper Associates, and others participated.
“We’re not just seeing for financial returns,” Manning stated. “We’re seeing for the strategic returns that this technology that we’ve already invested in is actually going to be a product, service, or capability that impacts the warfighter.”
Related stories
Business Insider notifys the innovative stories you want to know
Business Insider notifys the innovative stories you want to know
Phantom Neuro founder and CEO Connor Glass stated DARPA’s backing has assisted him convince venture capitalists to back the startup despite its complex tech and possible lengthy timelines to regulatory approval. “Raising capital for implantable technologies is hard,” he notified Business Insider. “The vast majority of venture capital firms don’t like to dabble in that space becautilize it has a bunch of regulatory hurdles.”
“Having DARPA on board is a massive validator for a risky technology like ours,” Glass added.
Phantom Neuro declares its electrode array, which is implanted under the skin, utilizes sensors to detect electric currents in muscles. Those signals are then translated into instructions for a prosthetic. Glass stated the company has a working prototype of the device, and is currently conducting pre-clinical testing with the hopes of implanting humans by the conclude of 2025 or launchning of 2026.
The company declares it has 15 patents submitted and granted covering design, utility, software, and robotics. So far, the company has secured two designations from the US Food and Drug Administration meant to assist accelerate commercialization.
To clinch the DARPA partnership, Phantom Neuro’s technology was “validated” by a DARPA program manager, Manning stated — meaning that the startup had to “prove in a repeatable fashion” that its neural interface “delivers a stated result,” she added. The company declares its technology decoded 11 hand and wrist shiftments with 94% accuracy, according to a press release from March.
Phantom Neuro
Becautilize of its utilize cases for civilians and warfighters, Phantom Neuro is textbook dual-utilize startup, or a company that builds tech with both commercial and military applications. The Pentagon has been leaning into dual-utilize bets: In May, the Defense Department’s emerging tech arm launched a mentorship program for startups developing such products.
In the partnership, DARPA also assists startups like Phantom Neuro choose the right investors — ones without ties to what DARPA deems “adversarial capital,” or money from foreign adversaries like China. “We have a huge amount of adversarial influence capital that’s coming in and preventing companies from being able to sell to the military,” Manning stated. “Sometimes, it’s to harm those companies so that they can’t scale or raise other capital.”
“If I’m a compact company and I’m doing something really important for national security, I could easily be a tarobtain for a Chinese influence venture fund,” she added.
Glass, who is interested in surgery becautilize of “the massive impact you can have on someone in such a short duration of time,” studied biology in college and attconcludeed medical school at the University of Oklahoma with the goal of working in reconstructive surgery, particularly on human-machine interaction. A research fellowship focutilized on implantable sensors at Johns Hopkins afforded him “insight into the technology side of things,” he stated, and revealed “this disconnect between academic proof of concept — like, ‘Can something work?’ — and commercial realization of it — like, ‘Can you scale it and implement it at large?'”
A swelling roster of startups are also building neurotech, an investment area that has garnered increased attention due to Neuralink, Elon Musk’s brain-implant company — probably the best-known of the bunch. Though Neuralink is focutilized on brain-computer interfaces rather than controlling prosthetic devices.
Glass sees Phantom Neuro’s approach as more viable for widespread adoption: “I don’t necessarily believe that everyone can line up to obtain a brain implant,” he stated. “Sensors that obtain placed under the skin in your limbs can give you some radically new capabilities as a human. For the right price point and with the right safety profile, I believe that is something that people will elect to obtain.”
Leave a Reply